See more : Tai Ping Carpets International Limited (TAPCF) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmonx Corporation (LUNG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmonx Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Fun Yours Technology Co.,Ltd. (6482.TWO) Income Statement Analysis – Financial Results
- Future Consumer Limited (FCONSUMER.NS) Income Statement Analysis – Financial Results
- Taiwan Semiconductor Co., Ltd. (5425.TWO) Income Statement Analysis – Financial Results
- China CIFCO Investment Co., Ltd (000996.SZ) Income Statement Analysis – Financial Results
- Playmates Holdings Limited (PYHOF) Income Statement Analysis – Financial Results
Pulmonx Corporation (LUNG)
About Pulmonx Corporation
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 68.68M | 53.66M | 48.42M | 32.73M | 32.60M | 20.00M |
| Cost of Revenue | 17.92M | 13.80M | 12.79M | 11.53M | 10.18M | 7.72M |
| Gross Profit | 50.75M | 39.87M | 35.63M | 21.20M | 22.41M | 12.29M |
| Gross Profit Ratio | 73.90% | 74.29% | 73.59% | 64.77% | 68.77% | 61.42% |
| Research & Development | 18.08M | 15.40M | 13.06M | 7.46M | 6.05M | 6.99M |
| General & Administrative | 89.81M | 77.01M | 64.77M | 44.57M | 34.20M | 20.35M |
| Selling & Marketing | 4.80M | 6.10M | 5.10M | 1.50M | 600.00K | 100.00K |
| SG&A | 94.61M | 83.11M | 69.87M | 46.07M | 34.20M | 20.35M |
| Other Expenses | 0.00 | -396.00K | -585.00K | 3.28M | -617.00K | -916.00K |
| Operating Expenses | 112.69M | 98.50M | 82.93M | 53.53M | 40.25M | 27.34M |
| Cost & Expenses | 130.61M | 112.30M | 95.72M | 65.07M | 50.43M | 35.06M |
| Interest Income | 5.57M | 1.53M | 400.00K | 213.00K | 432.00K | 21.00K |
| Interest Expense | 3.23M | 1.07M | 829.00K | 3.18M | 2.32M | 2.52M |
| Depreciation & Amortization | 1.95M | 4.00M | 3.16M | 400.00K | 1.20M | 270.00K |
| EBITDA | -55.09M | -55.99M | -46.62M | -28.44M | -16.82M | -15.68M |
| EBITDA Ratio | -80.22% | -107.16% | -98.09% | -88.10% | -54.17% | -78.37% |
| Operating Income | -61.94M | -58.64M | -47.30M | -32.33M | -17.84M | -15.05M |
| Operating Income Ratio | -90.19% | -109.27% | -97.70% | -98.77% | -54.73% | -75.24% |
| Total Other Income/Expenses | 1.66M | 67.00K | -1.01M | 314.00K | -2.50M | -3.42M |
| Income Before Tax | -60.27M | -58.57M | -48.32M | -32.02M | -20.34M | -18.47M |
| Income Before Tax Ratio | -87.76% | -109.15% | -99.80% | -97.82% | -62.40% | -92.32% |
| Income Tax Expense | 571.00K | 353.00K | 343.00K | 213.00K | 363.00K | 12.00K |
| Net Income | -60.84M | -58.92M | -48.66M | -32.23M | -20.70M | -18.48M |
| Net Income Ratio | -88.60% | -109.80% | -100.51% | -98.47% | -63.52% | -92.38% |
| EPS | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| EPS Diluted | -1.60 | -1.59 | -1.35 | -0.90 | -0.58 | -0.89 |
| Weighted Avg Shares Out | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
| Weighted Avg Shares Out (Dil) | 37.97M | 37.10M | 36.13M | 35.69M | 35.43M | 20.71M |
Pulmonx to Present at Upcoming September Investor Conferences
Pulmonx Corporation (LUNG) CEO Glen French on Q2 2022 Results - Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
Pulmonx: Interesting Technology But Struggling With Adoption
Pulmonx Corporation (LUNG) CEO Glendon French on Q1 2022 Results - Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference
Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022
Source: https://incomestatements.info
Category: Stock Reports